Literature DB >> 19048415

The catastrophic antiphospholipid syndrome in Serbia: diagnostic and management problems.

Ljudmila Stojanovich1.   

Abstract

Antiphospholipid antibodies (aPL) are a common cause of acquired thrombophilia, termed antiphospholipid syndrome (APS, Huges syndrome). Catastrophic antiphospholipid syndrome (CAPS, Asherson's syndrome) is an unusual form of APS characterized with multi-organ failure and high mortality. Fortunately, CAPS accounts for less than 1% of APS cases. The recurrence rate is low with a stable clinical course if these patients are treated with adequate anticoagulation therapy. Due to the rarity of the condition, an international registry of CAPS patients was created in 2000 supported by the European Forum on Antiphospholipid Antibodies held in Taormina, Italy at the Tenth International Congress on aPL. The objective of our study is to describe characteristics of 12 Serbian patients with CAPS included in the international CAPS registry.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19048415     DOI: 10.1007/s12016-008-8102-1

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  37 in total

Review 1.  Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients.

Authors:  R A Asherson; R Cervera; J C Piette; Y Shoenfeld; G Espinosa; M A Petri; E Lim; T C Lau; A Gurjal; A Jedryka-Góral; H Chwalinska-Sadowska; R J Dibner; J Rojas-Rodríguez; M García-Carrasco; J T Grandone; A L Parke; P Barbosa; C Vasconcelos; M Ramos-Casals; J Font; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  2001-11       Impact factor: 1.889

Review 2.  Catastrophic antiphospholipid syndrome: lessons from the "CAPS Registry"--a tribute to the late Josep Font.

Authors:  Ricard Cervera; Silvia Bucciarelli; Gerard Espinosa; José A Gómez-Puerta; Manuel Ramos-Casals; Yehuda Shoenfeld; Jean-Charles Piette; Ronald A Asherson
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691

Review 3.  The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.

Authors:  Eric J Boren; Gurtej S Cheema; Stanley M Naguwa; Aftab A Ansari; M Eric Gershwin
Journal:  J Autoimmun       Date:  2008 Feb-Mar       Impact factor: 7.094

Review 4.  To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system.

Authors:  Yehuda Shoenfeld
Journal:  J Autoimmun       Date:  2007-03-26       Impact factor: 7.094

Review 5.  Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome.

Authors:  Doruk Erkan
Journal:  Autoimmun Rev       Date:  2006-07-21       Impact factor: 9.754

6.  Autoantibody response to microsomal epoxide hydrolase in hepatitis C and A.

Authors:  Toshitaka Akatsuka; Nobuharu Kobayashi; Takashi Ishikawa; Takafumi Saito; Michiko Shindo; Masayoshi Yamauchi; Kazutaka Kurokohchi; Hitoshi Miyazawa; Hongying Duan; Toshiyuki Matsunaga; Tsugikazu Komoda; Christophe Morisseau; Bruce D Hammock
Journal:  J Autoimmun       Date:  2007-02-12       Impact factor: 7.094

7.  Long term outcome of catastrophic antiphospholipid syndrome survivors.

Authors:  D Erkan; R A Asherson; G Espinosa; R Cervera; J Font; J-C Piette; M D Lockshin
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

Review 8.  B cell targeted therapy in autoimmunity.

Authors:  Miri Blank; Yehuda Shoenfeld
Journal:  J Autoimmun       Date:  2007-03-27       Impact factor: 7.094

Review 9.  Preventive strategies in systemic lupus erythematosus.

Authors:  Andrea Doria; Silvia Arienti; Mariaelisa Rampudda; Mariagrazia Canova; Michele Tonon; Piercalo Sarzi-Puttini
Journal:  Autoimmun Rev       Date:  2007-12-03       Impact factor: 9.754

Review 10.  Stress as a trigger of autoimmune disease.

Authors:  Ljudmila Stojanovich; Dragomir Marisavljevich
Journal:  Autoimmun Rev       Date:  2007-11-29       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.